EUCTR2014-003965-11-NL进行中（未招募）不适用
Targeted therapy with Imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period. - ImPACT
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Histologically proven adenocarcinoma of the colon;
- •2. Confirmed eligibility for surgery with curative intent as deemed by the hospital’s multidisciplinary team (MDT) review;
- •3. High intratumoural gene expression of PDGFR-a, PDGFR-ß, PDGF-C and KIT according to our diagnostic RT-qPCR test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 27
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 27
排除标准
- •The presence of synchronous distant metastases;
- •Current hospital standard of care dictates that patient should undergo any neoadjuvant therapy;
- •Concurrent participation in another clinical trial using any medicinal product, or participation in such a trial in the period of three months prior to the current trial;
研究者
相似试验
已完成
2 期
Targeted therapy with imatinib for treatment of poor prognosis mesenchymal-type resectable colon cancer: a proof-of-concept study in the preoperative window period.colon cancerNL-OMON47074Oncologie27
终止
2 期
Imatinib as Pre-operative Anti-Colon Cancer Targeted TherapyColonic NeoplasmsNCT02685046UMC Utrecht5
进行中（未招募）
不适用
Imatinib treatment as therapy of neurofibromas in patients with NF1Patients with NF1 and plessiform neurofibromasMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-000869-21-ITISTITUTO NEUROLOGICO CARLO BESTA
已完成
2 期
The evaluation of therapeutic effects and adverse effects of Imatinib in Secondary Progressive Multiple SclerosisMultiple Sclerosis.Multiple sclerosis (MS), also known asIRCT201210231584N3Vice chancellor for research, Tehran University of Medical Sciences28
已完成
2 期
Effect of Imatinib Mesylate in patients undergone allogeneic bone marrow transplantation who show chronic coetaneous involvement Graft Versus-Host Disease.cutaneous cGVHD.Graft-versus-host reaction or diseaseIRCT201302261030N12Hematology-Oncology and SCT Research Center28